Multi-Cancer Studies
If it’s your first time on this website, please read the disclaimer section.
Oct 05 – Oct 12, 2026
Targeting CD6 in solid tumors: safety, early efficacy, and mechanistic insights from a proof-of-concept trial of itolizumab.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This first-in-human, two-arm, open-label proof-of-concept trial evaluated the anti-CD6 monoclonal antibody itolizumab in patients with advanced, heterogeneous solid tumors. Treatment comprised an induction phase (group A: 100 mg weekly for nine doses; group B: 200 mg biweekly for five doses) followed by maintenance (100 mg every 21 days for up to six doses), with safety as the primary endpoint and disease control, survival, and exploratory biomarkers as secondary objectives. No safety-related discontinuations, related serious adverse events, or unexpected toxicities occurred; disease control was achieved in 25% (group A) and 20% (group B), with 1-year survival rates of 26% and 15%, respectively. Mechanistically, itolizumab downregulated CD6, increased soluble CD6, promoted cytotoxic CD8/NK phenotypes, and enhanced in vitro killing of CD318+ cancer cells. The authors conclude that itolizumab has a favorable safety profile and supports further development as an immunomodulatory strategy for advanced solid tumors, particularly CD318-expressing tumors and combination regimens.
10.1136/jitc-2026-016182
Sep 28 – Oct 05, 2026
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This ongoing first-in-human phase 1 trial evaluated escalating doses of RO7589831, a first-in-class covalent WRN inhibitor, in 88 patients with MSI and/or deficient DNA mismatch repair advanced solid tumors. RO7589831 was administered once daily, twice daily (150-1,000 mg), or three-times daily (200-600 mg) to determine safety, tolerability, and the recommended phase 2 dose, with secondary endpoints including DCR, ORR, DOR, PFS, and OS. One dose-limiting toxicity occurred (grade 2 nausea in the 600-mg TID cohort), and the maximum tolerated dose was not identified; common TEAEs were mostly grade 1-2, with DCR of 74.2% (49/66), confirmed ORR of 10.6% (7/66), median DOR of 10.2+ months, median PFS of 6.7 months, and median OS of 17.6 months. The authors conclude that RO7589831 has a manageable safety profile and warrants further clinical testing, with 150-mg and 600-mg BID selected as RP2Ds.
10.1038/s41591-026-04657-3
Sep 21 – Sep 28, 2026
In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This prospective clinical trial examined the in vivo effects of anti-PD-1 (nivolumab) on HIV-specific CD8+ T cells in men with HIV and cancer on antiretroviral therapy. Using single-cell RNA sequencing, the study found that a single dose of anti-PD-1 increased HIV-specific CD8+ T cells in some but not all participants and significantly reshaped the T-cell landscape, including emergence of a progenitor-like central memory cluster with interferon-stimulated gene signature and increased Granzyme-H expression. An inverse relationship was observed between increased cell-associated viral RNA and the percentage of specific T-cell clusters prior to anti-PD-1 administration. The authors conclude that anti-PD-1 has multiple effects on both HIV-specific CD8+ T cells and HIV latency in people with HIV on ART.
10.1038/s41467-026-77373-8
Sep 07 – Sep 14, 2026
Phase 1a clinical trial of XRD-0394, a first-in-class dual ATM/DNA-PK inhibitor, in combination with palliative radiotherapy.
INT J RADIAT ONCOL · Q1 JOURNAL - RANK #14/212
This first-in-human, open-label, multicenter phase 1a dose-escalation trial evaluated the safety, pharmacokinetics, and pharmacodynamics of XRD-0394, a dual ATM/DNA-PK inhibitor, administered as a single dose (40, 80, or 160 mg) 90±30 minutes before fraction 2 of palliative radiotherapy in 12 participants. Primary endpoints were dose-limiting toxicities, tolerability, and achieving a prespecified plasma exposure target of ≥530 ng/mL. No DLTs occurred, the maximum tolerated dose was not reached, and treatment-related adverse events were limited to grade 1 nausea and diarrhea in 2 patients. The authors conclude that single-dose XRD-0394 can be safely combined with palliative radiotherapy at plasma exposures exceeding the target, supporting further fractionated multi-dose studies.
10.1016/j.ijrobp.2026.08.069
Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102.
CANCER IMMUNOL RES · Q1 JOURNAL - RANK #18/183
This phase 1, first-in-human, open-label, dose-escalation trial evaluated a single infusion of TAK-102, an autologous GPC3-targeted CAR T-cell therapy armored with IL-7 and CCL19, in 11 patients with advanced solid tumors refractory to standard therapies. Primary endpoints were safety outcomes (DLTs, AEs, AESIs). Results showed no DLTs, common hematologic AEs (neutropenia/leukopenia 81.8%) and grade 1-2 CRS (54.5%). No objective responses occurred; 5 patients had stable disease (DCR 45.5%), with one tumor reduction of 26.1% lasting 9 months. The authors conclude the therapy has manageable safety and early biological activity, warranting further study.
10.1158/2326-6066.CIR-25-0855
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This first-in-human, multicenter, open-label, non-randomized Phase 1 dose-escalation trial (NCT05013554) evaluated the safety, efficacy, pharmacokinetics, and pharmacodynamics of the HER2×CD3×CD28 trispecific T-cell engager SAR443216 in 40 participants with relapsed/refractory HER2-expressing solid tumors. The primary objective was to determine the maximum tolerated dose (MTD), with secondary objectives including PK, immunogenicity, and preliminary clinical activity. Treatment was administered intravenously at dose levels of 18-900 µg, with intraparticipant lead-in dosing; disease control rates were 34.5% and 36.4% in the 2-week and 3-week lead-in cohorts, respectively, with no objective responses observed and the MTD not reached. The study concluded that SAR443216 treatment was feasible and well tolerated, with manageable toxicity (97.5% any-grade TEAEs, 45% grade ≥3, 50% CRS), warranting further evaluation of its efficacy and safety.
10.1136/jitc-2025-014309
Aug 31 – Sep 07, 2026
Sustained effects of auricular point acupressure on chemotherapy-induced neuropathy: a randomized controlled trial follow-up study.
J CANCER SURVIV · Q1 JOURNAL - RANK #11/68
This prespecified secondary analysis of a randomized wait-list controlled trial evaluated the sustainability of auricular point acupressure (APA) effects on chemotherapy-induced neuropathy (CIN) for 3 months post-intervention. Adults with moderate or greater CIN received either mobile-supported APA (mAPA, n=80) or virtual APA (vAPA, n=75) during the initial 4-week treatment phase. Outcomes were analyzed using generalized estimating equations with multiple imputation; CIN severity (ICO) decreased by 3.10, 3.36, and 3.61 points in mAPA and by 2.88, 2.90, and 3.21 points in vAPA at 1, 2, and 3 months, respectively (all p<.001). The authors concluded that APA offers a durable, self-administered, nonpharmacologic option for managing CIN, warranting larger studies with longer follow-up and untreated comparison groups.
10.1007/s11764-026-02104-3
Aug 24 – Aug 31, 2026
A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This first-in-human, nonrandomized, multicenter phase 1 study evaluated nelistotug (anti-CD96 mAb) as monotherapy (Arm A) or in combination with dostarlimab (Arm B) and dostarlimab plus belrestotug (Arm F) in patients with advanced solid tumors. Patients received escalating intravenous doses every 3 weeks; primary endpoints were dose-limiting toxicities (DLTs) and adverse events, with secondary endpoints including objective response rate and pharmacokinetics. Among 72 patients, no DLTs were observed, enabling dose escalation to the recommended phase 2 dose of 1400 mg; one complete response and one partial response occurred in Arm B (3% each), with no responses in Arms A and F. The authors concluded that nelistotug had an acceptable safety profile but limited efficacy in this heavily pretreated population.
10.1158/1078-0432.CCR-25-4374
Efficacy and Safety of Adjusting Antimicrobial Therapy in Episodes of Fever and Neutropenia Catalogued as Fever of Unknown Origin in Children with Cancer: A Randomized Clinical Trial.
ANTIBIOTICS-BASEL · Q1 JOURNAL - RANK #17/137
This multicenter, prospective, noninferiority randomized clinical trial evaluated the efficacy and safety of maintaining versus adjusting antimicrobial therapy in pediatric cancer patients with febrile neutropenia (FN) classified as fever of unknown origin (FUO). A total of 266 of 939 FN episodes were FUO, and 231 with favorable early evolution were randomized (111 maintain, 120 adjust). The primary endpoint, uneventful resolution, was identical between groups: 96% (106/111) in the maintain arm versus 95% (114/120) in the adjust arm (p=1.00; RR 1.01, 95%CI 0.95-1.06; absolute risk difference 0.01, 95%CI -0.05-0.06). The authors conclude that adjusting antimicrobial therapy is safe in carefully selected FUO cases with favorable early evolution, supporting antimicrobial stewardship strategies.
10.3390/antibiotics15080779
Oxycodone combined with pulsed radiofrequency for refractory cancer pain from spinal metastases: a randomized controlled study.
SUPPORT CARE CANCER · Q1 JOURNAL - RANK #17/173
This randomized controlled trial assessed the efficacy and safety of oxycodone combined with pulsed radiofrequency (PRF) versus oxycodone alone for refractory cancer pain from spinal metastases in 60 patients. Patients were randomly assigned to receive oxycodone alone (n=30) or oxycodone plus PRF (n=30), with outcomes including Numerical Rating Scale (NRS) pain scores, breakthrough pain episodes, opioid consumption, immune parameters, and quality of life. The combination group showed significantly lower NRS scores, fewer breakthrough pain episodes, reduced opioid consumption (dose escalation rate 46.67% vs. 73.33%, p=0.035), better preserved T lymphocyte subsets, and a lower adverse reaction rate (43.33% vs. 70.00%, p=0.037), with no serious adverse events. The authors concluded that the combination may improve pain control and quality of life, but note the clinical significance of immune changes is unclear and require larger trials.
10.1007/s00520-026-11122-x
Aug 17 – Aug 24, 2026
Effects of aromatherapy on chemotherapy-related symptom management.
SUPPORT CARE CANCER · Q1 JOURNAL - RANK #17/173
This four-arm, randomized, blinded clinical trial evaluated the feasibility and preliminary efficacy of aromatherapy for managing chemotherapy-related symptoms in 91 cancer patients (≥8 years). Participants were randomized to lavender, jojoba, orange, or ginger inhalers and reported symptom severity across seven symptoms over two chemotherapy cycles. Feasibility was demonstrated with an 81.0% retention rate (68/84) and 83.3% compliance, while mean composite symptom severity scores decreased by -1.38 (SE=0.54) from baseline to Cycle 2. The authors concluded that aromatherapy is a feasible and acceptable non-pharmacologic intervention, warranting further validation studies.
10.1007/s00520-026-11118-7
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This first-in-human, open-label, phase I trial evaluated intratumoral MEDI1191 (IL-12 mRNA lipid nanoparticle) plus intravenous durvalumab in 61 patients with advanced solid tumors who had progressed on prior therapy. The primary objectives were safety and maximum tolerated dose determination; secondary included efficacy. Treatment-emergent adverse events occurred in 96.7% of patients, with 41.0% Grade 3/4, but no dose-limiting toxicities and MTD was not reached. The objective response rate was 9.8% (1 complete response, 5 partial responses), with responses in injected and distant lesions, including in prior anti-PD-(L)1-treated patients, indicating promising preliminary antitumor activity.
10.1158/1078-0432.CCR-25-4865
Validating the minimal clinically important difference for the Edmonton Symptom Assessment Scale (ESAS) total symptom distress score (TSDS).
J PAIN SYMPTOM MANAG · Q1 JOURNAL - RANK #53/332
This study validates the minimal clinically important difference (MCID) for the Edmonton Symptom Assessment Scale total symptom distress score using data from two randomized controlled trials of medicinal cannabis in advanced cancer. The analysis included 186 patients with incurable cancer, using the Patient Global Impression scale as an anchor and both anchor-based and distribution-based methods. For improvement, the within-patient change method yielded an MCID of -6.6 points, the sensitivity-specificity approach identified a cutoff of a decrease of at least 4 points, and distribution-based estimates were 4.25 and 7.08 points. The results support previously established MCID values, but the deterioration sample was too small for meaningful conclusions.
10.1016/j.jpainsymman.2026.08.009